Neves R J, Zincke H
Br J Urol. 1987 May;59(5):390-5. doi: 10.1111/j.1464-410x.1987.tb04832.x.
Fifty-four patients with renal cancer and vena cava tumour thrombus underwent radical nephrectomy and removal of the thrombus; the operative mortality rate was 9.3% (5 patients). The extent of the vena cava thrombus did not affect survival. Of 36 patients with no known pre-operative metastases and complete (29 patients) and incomplete (7 patients) removal of the vena cava tumour thrombus, the 5-year survival rate was 68 and 17%, respectively (P = 0.01). Thirteen patients (45%) who underwent complete removal of the vena cava tumour thrombus are alive and free of disease, with a mean follow-up of 51.2 months (range 4-144); three died without disease 110, 31 and 23 months after operation. The 2-year and 5-year survival rates of 18 patients with known pre-operative metastases was 37.5 and 12.5% respectively; 14 died between 1 and 27 months post-operatively (mean 11.6) of metastatic disease. Two of these 18 patients experienced long-term remission: one died of unrelated causes 151 months after operation; the other was lost to follow-up 219 months after operation, with no evidence of disease. Of 14 patients with positive regional nodes, the mean survival in those with metastases compared with those without metastases was 7.5 versus 15 months, respectively; only one patient survived at 14 months. Operative intervention in patients without metastatic disease (systemic or regional) and complete removal of the vena cava thrombus achieved a 5-year survival rate of 68%. Variables which significantly decreased survival and may be considered contraindications for operation were systemic metastasis, regional lymph node involvement and incomplete removal of the vena cava thrombus.
54例患有肾癌合并腔静脉瘤栓的患者接受了根治性肾切除术及瘤栓清除术;手术死亡率为9.3%(5例患者)。腔静脉瘤栓的范围不影响生存率。36例术前无已知转移且腔静脉瘤栓完全清除(29例患者)和不完全清除(7例患者)的患者,其5年生存率分别为68%和17%(P = 0.01)。13例(45%)接受腔静脉瘤栓完全清除术的患者存活且无疾病,平均随访51.2个月(范围4 - 144个月);3例在术后110、31和23个月无疾病死亡。18例术前已知有转移的患者,其2年和5年生存率分别为37.5%和12.5%;14例在术后1至27个月(平均11.6个月)死于转移性疾病。这18例患者中有2例出现长期缓解:1例在术后151个月死于无关原因;另1例在术后219个月失访,无疾病证据。14例区域淋巴结阳性的患者中,有转移者与无转移者的平均生存期分别为7.5个月和15个月;只有1例患者在14个月时存活。对无转移性疾病(全身或区域)且腔静脉瘤栓完全清除的患者进行手术干预,5年生存率为68%。显著降低生存率且可被视为手术禁忌证的变量为全身转移、区域淋巴结受累及腔静脉瘤栓清除不完全。